Beigene Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BEIGENE, and what generic alternatives to BEIGENE drugs are available?
BEIGENE has one approved drug.
There are twelve US patents protecting BEIGENE drugs.
There are sixty-six patent family members on BEIGENE drugs in thirty countries and thirteen supplementary protection certificates in twelve countries.
Summary for Beigene
International Patents: | 66 |
US Patents: | 12 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Patent Litigation for Beigene: | See patent lawsuits for Beigene |
PTAB Cases with Beigene as petitioner: | See PTAB cases with Beigene as petitioner |
Drugs and US Patents for Beigene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,142,528 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,884,674 | ⤷ Subscribe | ⤷ Subscribe | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,591,340 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beigene Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 3034326 | ⤷ Subscribe |
Finland | 3500299 | ⤷ Subscribe |
Norway | 2022005 | ⤷ Subscribe |
South Africa | 201900919 | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2014173289 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beigene Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2989106 | 2290500-4 | Sweden | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1576 20211123 |
2989106 | C02989106/01 | Switzerland | ⤷ Subscribe | FORMER OWNER: BEIGENE, LTD., KY |
2989106 | C202230011 | Spain | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122 |
2989106 | CR 2022 00008 | Denmark | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123 |
2989106 | LUC00250 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1576 20211123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.